BSECompany Update1 Sept 2026 · 1 Sept 2026, 11:01 am

Amendment to MOA of the company was approved by Board of Directors. The Proposed change in MOA of the company is subject to necessary approvals from Ministry of Corporate Affairs, Shareholders ....

Godavari Drugs Ltd · 530317

✦ AI SummaryM&A

Godavari Drugs Ltd has approved an alteration to its Memorandum of Association to include a new Main Object for the business of nutraceuticals, dietary supplements, and allied products. The alteration requires approval from the shareholders by way of a Special Resolution at the 38th Annual General Meeting scheduled for September 25, 2026.

Analysis Scores

Earnings Impact5/10
Growth Catalyst6/10
Governance Concern2/10
Regulatory Risk4/10
Balance Sheet Risk3/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Godavari Drugs Ltd - 530317 - Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association

Attachments (1)

📄

3e817cb0-c599-4969-bb86-eb9fed014c5c.pdf

pdf

Download →
View document text
GODAVARI DRUGS LIMITED Regd. Off.:‘Mayfair’, S.P. Road, Secunderabad - 500 003. TS, India. Voice: +91-40-2784 9700/ 2784 2602/ 2784 4557 Email: info@godavaridrugs.com / Website: www.godavaridrugs.com To, Date: 31.08.2026 BSE Limited, P.J. Towers, Dalal Street, Mumbai – 400001 Dear Sir/Madam Unit: Godavari Drugs Limited (Scrip Code: 530317) Sub: Outcome of Board Meeting held on 31.08.2026 With reference to the subject cited this is to inform the Exchange that the Board of Directors of Godavari Drugs Limited, at its Meeting held on Monday, 31st August, 2026, at 6:30 p.m. through Video Conferencing, considered and approved the following: 1. Alteration of the Main Objects Clause III(A) of the Memorandum of Association of the Company by insertion of a new Main Object No. 4, relating to the business of nutraceuticals, dietary supplements, natural extracts, food ingredients and allied products, subject to the approval of the Members by way of a Special Resolution at the ensuing 38th Annual General Meeting of the Company. (Details attached in Annexure - A) 2. Revised Notice convening the 38th Annual General Meeting of the Company scheduled to be held on Friday, 25th September, 2026 at 03.00 p.m. through Video-Conferencing ("VC") / Other Audio Visual Means ("OAVM"). Details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, in respect of the alteration of the Memorandum of Association, are enclosed as Annexure - A. The meeting commenced at 6:30 p.m. and concluded at 06.45 p.m. This is for the information and records of the Exchange, please Thanking you. Yours faithfully, For Godavari Drugs Limited Venkatesh Achanta Company Secretary & Compliance Officer Plant: A6/2, MIDC, Nanded – 431603, Maharastra, India. Email: nnd@godvaridrugs.com CIN: L24230TG1987PLC008016 GODAVARI DRUGS LIMITED Regd. Off.:‘Mayfair’, S.P. Road, Secunderabad - 500 003. TS, India. Voice: +91-40-2784 9700/ 2784 2602/ 2784 4557 Email: info@godavaridrugs.com / Website: www.godavaridrugs.com ANNEXURE - A Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Alteration of the Memorandum of Association of the Company S No. Particulars Details 1. Alteration of Memorandum of Insertion of a new Main Object No. 4 under Clause III(A) Association – nature of (Main Objects) of the Memorandum of Association of the amendment Company. No existing clause has been deleted or modified. 2. Date of approval by the Board 31.08.2026 of Directors 3. Brief details of the amendment The following new object is proposed to be inserted as Main Object No. 4 under Clause III(A): "To manufacture, process, formulate, purchase, sell, import, export, market and distribute nutraceuticals, dietary supplements, health supplements, natural extracts, herbal extracts, botanical extracts, standardised plant extracts, food ingredients, food additives, functional foods and allied products, whether through own manufacturing, third- party/contract manufacturing or on loan license basis." 4. Rationale / reason for the The Company proposes to enter into the business of domestic amendment and export marketing, third-party/contract manufacturing and own manufacturing of bulk ingredients and formulations of Nutraceuticals, Natural Extracts and Food Ingredients. The existing Main Objects Clause III(A) covers drugs and pharmaceuticals and does not explicitly authorise the proposed line of business, which is governed under the Food Safety and Standards Act, 2006. The alteration is required to enable the Company to validly carry on the proposed business. 5. Whether the amendment Yes. The amendment requires approval of the Members by requires approval of the way of a Special Resolution under Section 13 of the shareholders Companies Act, 2013. 6. Manner in which shareholder By way of a Special Resolution to be placed before the approval is proposed to be Members at the 38th Annual General Meeting of the obtained Company scheduled to be held on Friday, 25th September, 2026 at 03.00 p.m. through VC / OAVM. 7. Effect of the amendment on The alteration is additive in nature. The Company does not the existing business / propose to discontinue or abandon any of its existing business shareholders activities. The alteration does not affect the existing rights of the Members or the nature of their liability. 8. Effective date of the The amendment shall take effect upon approval of the amendment Members by Special Resolution at the 38th Annual General Meeting to be held on 25.09.2026 and upon filing of Form MGT-14 with the Registrar of Companies, Telangana. Plant: A6/2, MIDC, Nanded – 431603, Maharastra, India. Email: nnd@godvaridrugs.com CIN: L24230TG1987PLC008016